Patients Coming Off Slimming Injections Put On Weight Four Times Faster Than Dieters

Fresh analysis indicates that patients who stop using blockbuster slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who end traditional lifestyle programs.

Research printed in a major medical journal points out that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month after stopping.

"Users using such drugs must be cognizant of the potential of quick rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.

This pace of regain implies a return to original mass in about a year and a half.

Weighing Therapies

The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with other pills.

The team emphasize that people who lose weight through diet and exercise generally have a less rapid creep back—around 0.1 kg a month—post-intervention.

The Reason for the Quick Regain

Doctors propose the way of the jabs explains the heightened regain.

The injections mimic a natural hormone called GLP-1, which moderates appetite.

"Sustained high doses of GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.

"Withdrawal of this hormone supplement leads to hunger is uncontrolled, making overeating far more likely."

A Lifelong Condition?

Health authorities recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.

Many experts say that, due to the high risk of weight regain, the treatment is often life-long.

This view is supported by drug manufacturers, who state that the results "highlight the long-term nature of excess weight," comparing it to managing conditions like diabetes.

User Testimonies

Individuals who have discontinued the jabs describe a sudden resurgence of cravings.

"I experienced something activating and I was suddenly starving," said one woman.

This difficulty is worsened if users have not adopted lasting lifestyle or habit modifications during therapy.

Widespread Interest

Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.

• Adoption is more common among females than males.
• The middle-aged age group shows the highest level of interest.
• Many obtain the drugs through private healthcare rather than public health services.

Finally, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and long-term success hinges on integrated lifestyle management.